Background Chronic kidney disease (CKD) is a frequent, under-recognized condition and a
risk factor for renal failure and cardiovascular disease. Increasing evidence connects non …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is
strongly associated with the metabolic syndrome. In the last decade, it has become apparent …

The evolution of mobile phone technology has introduced new possibilities to the field of
medicine. Combining technological advances with medical expertise has led to the use of …

Background & Aims Chronic liver disease (CLD) and cirrhosis are associated with immune
dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes …

Correspondence 390 www. thelancet. com/gastrohep Vol 7 May 2022 at least two different
mechanisms of action. Views were divided on the failure of immunomodulators, with 252 …

[1] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet …

Background & Aims Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 …

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is a common cause of
abnormal LFTs in primary care, but there are no data defining its contribution nor reporting …

Background Despite concerns that patients with liver transplants might be at increased risk
of adverse outcomes from COVID-19 because of coexisting comorbidities and use of …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …